Talazoparib: all 93 studies that test it
Page 1 of 1. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideRecruitingNCT06844383Phase 2
- Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate CancerRecruitingNCT06582628Phase 2
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
- FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) TestRecruitingNCT06193525Phase 2
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingNCT05873192Phase 2
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid LeukemiaNot yet recruitingNCT05319249Phase 1/2
- Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) SignatureRecruitingNCT05288127Phase 2
- Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and EfficacyRecruitingNCT05101551Phase 1
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian CancerRecruitingNCT05071937Phase 2
- PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine TumoursRecruitingNCT05053854Phase 1
- Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)RecruitingNCT05035745Phase 1/2
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaRecruitingNCT04901702Phase 1/2
- Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant DeficiencyRecruitingNCT04892693Phase 2
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingNCT04734730Phase 2
- TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaRecruitingNCT04678362Phase 2
- Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT04511039Phase 1
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
- Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialRecruitingNCT03990896Phase 2
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersRecruitingNCT03968406Phase 1
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 TrialActive, not recruitingNCT05142241Phase 2Results posted
- Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerTerminatedNCT04849364Phase 2Results posted
- A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerTerminatedNCT04690855Phase 2Results posted
- STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORSCompletedNCT04635631Phase 1Results posted
- BrUOG 390: Neoadjuvant Treatment With TalazoparibTerminatedNCT04598321Phase 1Results posted
- Study of RP-3500, Camonsertib, in Advanced Solid TumorsCompletedNCT04497116Phase 1/2Results posted
- Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
- Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesCompletedNCT04187833Phase 2Results posted
- Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
- Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT04068831Phase 2Results posted
- Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsTerminatedNCT04052204Phase 1/2Results posted
- A Study of the Drugs Talazoparib and Temozolomide in Prostate CancerTerminatedNCT04019327Phase 1/2Results posted
- A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerTerminatedNCT03901469Phase 2Results posted
- Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsTerminatedNCT03875313Phase 1/2Results posted
- A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid TumorsTerminatedNCT03637491Phase 1/2Results posted
- Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid TumorsTerminatedNCT03565991Phase 2Results posted
- Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast CancerTerminatedNCT03499353Phase 2Results posted
- Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCActive, not recruitingNCT03395197Phase 3Results posted
- Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT03377556Phase 2Results posted
- A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid TumorsCompletedNCT03343054Phase 1Results posted
- A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerCompletedNCT03148795Phase 2Results posted
- A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid TumorsCompletedNCT03077607Phase 1Results posted
- A Study of Talazoparib in Patients With Advanced Solid TumorsCompletedNCT03070548Phase 1Results posted
- A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid TumorsCompletedNCT03042910Phase 1Results posted
- An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)CompletedNCT02997176Phase 1Results posted
- An Open-Label Pharmacokinetics and Safety Study of TalazoparibCompletedNCT02997163Phase 1Results posted
- Open-Label Extension and Safety Study of TalazoparibCompletedNCT02921919Phase 2Results posted
- Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingNCT02912572Phase 2Results posted
- Decitabine and Talazoparib in Untreated AML and R/R AMLCompletedNCT02878785Phase 1/2Results posted
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid TumorsCompletedNCT02401347Phase 2Results posted
- BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor TreatmentTerminatedNCT02326844Phase 2Results posted
- Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast CancerCompletedNCT02282345Phase 2Results posted
- Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent MalignanciesCompletedNCT02116777Phase 1/2Results posted
- A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)TerminatedNCT02034916Phase 2Results posted
- Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsCompletedNCT01989546Phase 1/2Results posted
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)CompletedNCT01945775Phase 3Results posted
- Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsCompletedNCT01286987Phase 1Results posted
- Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerSuspendedNCT05425862Phase 1
- Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET TrialActive, not recruitingNCT05327010Phase 2
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCActive, not recruitingNCT04846478Phase 1
- Telaglenastat + Talazoparib In Prostate CancerWithdrawnNCT04824937Phase 2
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCActive, not recruitingNCT04821622Phase 3
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast CancerWithdrawnNCT04756765Phase 2
- Talazoparib Maintenance Therapy in Triple-negative Breast CancerStatus unknownNCT04755868Phase 2
- Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRdCompletedNCT04740190Phase 2
- Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerCompletedNCT04703920Phase 1
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
- Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOtheliomaStatus unknownNCT04462809Phase 2
- Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerActive, not recruitingNCT04334941Phase 2
- Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)CompletedNCT04332744Phase 2
- Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
- Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerCompletedNCT04134884Phase 1
- Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.Active, not recruitingNCT04039230Phase 1/2
- TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerActive, not recruitingNCT03964532Phase 1/2
- Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersActive, not recruitingNCT03911973Phase 1/2
- Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT03672773Phase 2
- Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid TumorsWithdrawnNCT03426254Phase 1
- Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
- Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
- Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid TumorsWithdrawnNCT02537561Phase 1
- Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast CancerTerminatedNCT02358200Phase 1
- Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced CancerCompletedNCT02317874Phase 1
- Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
- Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA GenesActive, not recruitingNCT02286687Phase 2
- A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncerWithdrawnNCT02127151Phase 2
- Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male VolunteersCompletedNCT01776437Phase 1
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesCompletedNCT01399840Phase 1